Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (6): 504-507.DOI: 10.3969/j.issn.1673-8640.2017.06.013
• Orginal Article • Previous Articles Next Articles
Received:
2016-03-28
Online:
2017-06-30
Published:
2017-07-04
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.06.013
组别(岁) | 例数(男/女) | WBC(×109/L) | RBC(×1012/L) | PLT(×109/L) | Hb(g/L) | ||||
---|---|---|---|---|---|---|---|---|---|
2~ | 968/670 | 8.8(5.5~13.8) | 4.63(4.06~5.62) | 307(187~495) | 122(103~137) | ||||
3~ | 654/476 | 8.3(5.1~13.1) | 4.63(4.06~5.62) | 299(183~482) | 125(108~139) | ||||
4~ | 232/169 | 8.4(5.3~13.7) | 4.63(4.04~5.67) | 311(193~500) | 126(109~141) | ||||
5~ | 212/137 | 8.5(5.0~13.5) | 4.67(4.02~5.60) | 313(201~487) | 126(102~143) | ||||
6~ | 172/124 | 8.2(4.7~13.4) | 4.71(4.10~5.76) | 314(213~490) | 128(106~145) | ||||
2~6 | 2 238/1 576 | 8.5(5.3~13.5) | 4.64(4.06~5.63) | 306(190~489) | 124(105~140) | ||||
组别(岁) | MCV(fL) | MCH(pg) | MCHC(g/L) | HCT | |||||
2~ | 79(59~86) | 27(19~29) | 337(316~354) | 0.36(0.32~0.41) | |||||
3~ | 80(60~87) | 27(19~29) | 339(319~356) | 0.37(0.33~0.41) | |||||
4~ | 80(61~88) | 27(20~29) | 339(320~360) | 0.37(0.33~0.41) | |||||
5~ | 80(58~87) | 27(19~30) | 339(321~358) | 0.37(0.31~0.42) | |||||
6~ | 81(60~88) | 28(20~30) | 339(319~359) | 0.38(0.33~0.43) | |||||
2~6 | 80(59~87) | 27(19~29) | 338(318~356) | 0.37(0.32~0.41) |
组别(岁) | 例数(男/女) | WBC(×109/L) | RBC(×1012/L) | PLT(×109/L) | Hb(g/L) | ||||
---|---|---|---|---|---|---|---|---|---|
2~ | 968/670 | 8.8(5.5~13.8) | 4.63(4.06~5.62) | 307(187~495) | 122(103~137) | ||||
3~ | 654/476 | 8.3(5.1~13.1) | 4.63(4.06~5.62) | 299(183~482) | 125(108~139) | ||||
4~ | 232/169 | 8.4(5.3~13.7) | 4.63(4.04~5.67) | 311(193~500) | 126(109~141) | ||||
5~ | 212/137 | 8.5(5.0~13.5) | 4.67(4.02~5.60) | 313(201~487) | 126(102~143) | ||||
6~ | 172/124 | 8.2(4.7~13.4) | 4.71(4.10~5.76) | 314(213~490) | 128(106~145) | ||||
2~6 | 2 238/1 576 | 8.5(5.3~13.5) | 4.64(4.06~5.63) | 306(190~489) | 124(105~140) | ||||
组别(岁) | MCV(fL) | MCH(pg) | MCHC(g/L) | HCT | |||||
2~ | 79(59~86) | 27(19~29) | 337(316~354) | 0.36(0.32~0.41) | |||||
3~ | 80(60~87) | 27(19~29) | 339(319~356) | 0.37(0.33~0.41) | |||||
4~ | 80(61~88) | 27(20~29) | 339(320~360) | 0.37(0.33~0.41) | |||||
5~ | 80(58~87) | 27(19~30) | 339(321~358) | 0.37(0.31~0.42) | |||||
6~ | 81(60~88) | 28(20~30) | 339(319~359) | 0.38(0.33~0.43) | |||||
2~6 | 80(59~87) | 27(19~29) | 338(318~356) | 0.37(0.32~0.41) |
组别 | 例数(男/女) | WBC(×109/L) | RBC(×1012/L) | PLT(×109/L) | Hb(g/L) |
---|---|---|---|---|---|
新生儿组 | 330/300 | 10.4(5.4~16.1) | 4.29(3.07~5.71) | 380(173~685) | 138(103~137) |
婴儿组 | 1 893/1 426 | 9.3(5.7~13.8) | 4.55(3.89~5.54) | 371(218~627) | 115(93~132) |
幼儿组 | 2 238/1 576 | 8.5(5.3~13.5) | 4.64(4.06~5.63) | 306(190~489) | 124(105~140) |
儿童组 | 407/322 | 7.6(4.9~12.5) | 4.71(4.05~5.74) | 293(186~463) | 131(109~147) |
组别 | 例数(男/女) | WBC(×109/L) | RBC(×1012/L) | PLT(×109/L) | Hb(g/L) |
---|---|---|---|---|---|
新生儿组 | 330/300 | 10.4(5.4~16.1) | 4.29(3.07~5.71) | 380(173~685) | 138(103~137) |
婴儿组 | 1 893/1 426 | 9.3(5.7~13.8) | 4.55(3.89~5.54) | 371(218~627) | 115(93~132) |
幼儿组 | 2 238/1 576 | 8.5(5.3~13.5) | 4.64(4.06~5.63) | 306(190~489) | 124(105~140) |
儿童组 | 407/322 | 7.6(4.9~12.5) | 4.71(4.05~5.74) | 293(186~463) | 131(109~147) |
地区 | 年龄(岁) | WBC(×109/L) | RBC(×1012/L) | PLT (×109/L) | Hb (g/L) | MCV (fL) | MCH (pg) | MCHC (g/L) | HCT | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
厦门 | 2~6 | 5.3~13.5 | 4.06~5.63 | 190~489 | 105~140 | 59~87 | 19~29 | 318~356 | 0.32~0.41 | |||||
上海 | 2~6 | 4.8~11.6 | 3.75~5.18 | 175~460 | 110~145 | 76~88 | 25~31 | 329~368 | 0.31~0.41 | |||||
重庆 | 2~6 | 5.4~13.1 | 4.10~5.60 | 168~461 | 115~149 | 76~93 | 24~31 | 303~340 | 0.34~0.47 | |||||
南京 | 2~5 | 4.2~13.2 | 3.92~5.27 | 135~411 | 102~145 | 71~90 | 23~31 | 313~356 | 0.31~0.43 | |||||
组别 | MCV(fL) | MCH(pg) | MCHC(g/L) | HCT | ||||||||||
新生儿组 | 97(78~113) | 33(26~37) | 338(321~364) | 0.40(0.31~0.59) | ||||||||||
婴儿组 | 77(57~85) | 26(18~29) | 332(307~352) | 0.35(0.29~0.39) | ||||||||||
幼儿组 | 80(59~87) | 27(19~29) | 338(318~356) | 0.37(0.32~0.41) | ||||||||||
儿童组 | 82(61~89) | 28(20~30) | 341(318~360) | 0.38(0.33~0.43) |
地区 | 年龄(岁) | WBC(×109/L) | RBC(×1012/L) | PLT (×109/L) | Hb (g/L) | MCV (fL) | MCH (pg) | MCHC (g/L) | HCT | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
厦门 | 2~6 | 5.3~13.5 | 4.06~5.63 | 190~489 | 105~140 | 59~87 | 19~29 | 318~356 | 0.32~0.41 | |||||
上海 | 2~6 | 4.8~11.6 | 3.75~5.18 | 175~460 | 110~145 | 76~88 | 25~31 | 329~368 | 0.31~0.41 | |||||
重庆 | 2~6 | 5.4~13.1 | 4.10~5.60 | 168~461 | 115~149 | 76~93 | 24~31 | 303~340 | 0.34~0.47 | |||||
南京 | 2~5 | 4.2~13.2 | 3.92~5.27 | 135~411 | 102~145 | 71~90 | 23~31 | 313~356 | 0.31~0.43 | |||||
组别 | MCV(fL) | MCH(pg) | MCHC(g/L) | HCT | ||||||||||
新生儿组 | 97(78~113) | 33(26~37) | 338(321~364) | 0.40(0.31~0.59) | ||||||||||
婴儿组 | 77(57~85) | 26(18~29) | 332(307~352) | 0.35(0.29~0.39) | ||||||||||
幼儿组 | 80(59~87) | 27(19~29) | 338(318~356) | 0.37(0.32~0.41) | ||||||||||
儿童组 | 82(61~89) | 28(20~30) | 341(318~360) | 0.38(0.33~0.43) |
[1] | 陈喜军,陈发林,王友基.福建省三级医院临床检验互认项目参考区间现况[J].检验医学,2016,31(5):419-422. |
[2] | MONAGLE P,BARNES C,IGNJATOVIC V,et a1.Development haemostasis. Impact for clinical haemostasis laboratories[J].Thromb Haemost,2006,95(2):362-372. |
[3] | Clinical and Laboratory Standards Institute.Defining,establishing,and verifying reference intervals in the clinical laboratory[S]. C28-A3,CLSI,2008. |
[4] | Clinical and Laboratory Standards Institute.How to define and determine reference internals in the clinic laboratory[S]. C28-A2,CLSI,2000. |
[5] | SINTON T J,COWLEY D M,BRYANT S J.Reference intervals for calcium,phosphate,and alkaline phosphatase as derived on the basis of multichannel-analyzer profiles[J].Clin Chem,1986,32(1 Pt 1):76-79. |
[6] | 高原,杨剑敏,王欢,等.上海市区2 408例健康儿童末梢血血常规参数的参考区间调查分析[J].检验医学,2012,27(3):217-220. |
[7] | 李春莉,杨桂林,王艳妮,等.重庆市3~6岁健康儿童末梢血细胞参考范围调查[J].国际检验医学杂志,2012,33(24):2994-2995. |
[8] | 李松涛,唐吟岫,徐静华,等.南京地区2~5岁健康儿童末梢血血常规参考范围调查[J].广东医学,2014,52(8):1247-1248. |
[9] | KATAYEV A,BALCIZA C,SECCOMBE D W.Establishing reference intervals for clinical laboratory test results:is there a better way?[J].Am J Clin Pathol,2010,133(2):180-186. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||